Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov, NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome unsuitable for intensive chemotherapy. Glasdegib 100 mg (oral, QD) was administered continuously in 28-day cycles; LDAC 20 mg (subcutaneous, BID) was administered for 10 per 28 days. Patients (stratified by cytogenetic risk) were randomized (2:1) to receive glasdegib/LDAC or LDAC. The primary endpoint was overall survival. Eighty-eight and 44 patients were randomized to glasdegib/LDAC and LDAC, respectively. Median (80% confidence interval [CI]) overall survival was 8.8 (6.9-9.9) months with glasdegib/LDAC and 4.9 (3.5-6.0) months with LDAC (hazard ratio, 0.51; 80% CI, 0.39-0.67, P = 0.0004). Fifteen (17.0%) and 1 (2.3%) patients in the glasdegib/LDAC and LDAC arms, respectively, achieved complete remission (P < 0.05). Nonhematologic grade 3/4 all-causality adverse events included pneumonia (16.7%) and fatigue (14.3%) with glasdegib/LDAC and pneumonia (14.6%) with LDAC. Clinical efficacy was evident across patients with diverse mutational profiles. Glasdegib plus LDAC has a favorable benefit-risk profile and may be a promising option for AML patients unsuitable for intensive chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Sekulic, A., Migden, M. R., Oro, A. E., Dirix, L., Lewis, K. D., Hainsworth, J. D., Solomon, J. A., Yoo, S., Arron, S. T., Friedlander, P. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113713 · Cited by 1,464
Kantarjian, H. M., Thomas, X. G., Dmoszynska, A., Wierzbowska, A., Mazur, G., Mayer, J., Gau, J.-P., Chou, W.-C., Buckstein, R., Cermak, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9429 · Cited by 1,169
Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991
DiNardo, C. D., Pratz, K. W., Letai, A., Jonas, B. A., Wei, A. H., Thirman, M., Arellano, M., Frattini, M. G., Kantarjian, H., Popovic, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30010-x · Cited by 722
Self-citationBurnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007) · Cancer · doi:10.1002/cncr.22496 · Cited by 619
Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E., Garcia‐Manero, G., Wierda, W., Pierce, S., Shan, J., et al. (2006) · Cancer · doi:10.1002/cncr.21723 · Cited by 610
Self-citationMigden, M. R., Guminski, A., Gutzmer, R., Dirix, L., Lewis, K. D., Combemale, P., Herd, R. M., Kudchadkar, R., Trefzer, U., Gogov, S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70100-2 · Cited by 440
Hy's law: predicting serious hepatotoxicity
Temple, R. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1211 · Cited by 352
Döhner, H., Lübbert, M., Fiedler, W., Fouillard, L., Haaland, A., Brandwein, J. M., Lepretre, S., Reman, O., Turlure, P., Ottmann, O. G., et al. (2014) · Blood · doi:10.1182/blood-2014-03-560557 · Cited by 231
Self-citationJabbour, E., Kantarjian, H., O’Brien, S., Cortes, J., Giles, F., Faderl, S., Garcia-Manero, G., Wierda, W., Pierce, S., Shan, J., et al. (2005) · Blood · doi:10.1182/blood.v106.11.1846.1846 · Cited by 183
Self-citationBurnett, A. K., Hills, R. K., Hunter, A. E., Milligan, D., Kell, W. J., Wheatley, K., Yin, J., McMullin, M. F., Dignum, H., Bowen, D., et al. (2013) · Leukemia · doi:10.1038/leu.2012.229 · Cited by 161
Targeting hedgehog in hematologic malignancy
Irvine, D. A., & Copland, M. (2012) · Blood · doi:10.1182/blood-2011-10-383752 · Cited by 154
Hedgehog signaling maintains chemoresistance in myeloid leukemic cells
Queiroz, K. C. S., Ruela-de-Sousa, R. R., Fuhler, G. M., Aberson, H. L., Ferreira, C. V., Peppelenbosch, M. P., & Spek, C. A. (2010) · Oncogene · doi:10.1038/onc.2010.375 · Cited by 152
Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Adults
Klepin, H. D., Rao, A. V., & Pardee, T. S. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1564 · Cited by 146
Fukushima, N., Minami, Y., Kakiuchi, S., Kuwatsuka, Y., Hayakawa, F., Jamieson, C., Kiyoi, H., & Naoe, T. (2016) · Cancer Science · doi:10.1111/cas.13019 · Cited by 145
Cortes, J. E., Smith, B. D., Wang, E. S., Merchant, A. A., Oehler, V. G., Arellano, M. L., DeAngelo, D. J., Pollyea, D. A., Sekeres, M. A., Robak, T., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25238 · Cited by 123
Self-citationSavona, M. R., Pollyea, D. A., Stock, W., Oehler, V. G., Schroeder, M. A., Lancet, J. E., McCloskey, J. K., Kantarjian, H. M., Ma, W. W., Shaik, M. N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2824 · Cited by 108
Self-citationGLI2 inhibition abrogates human leukemia stem cell dormancy
Sadarangani, A., Pineda, G., Lennon, K. M., Chun, H.-J. E., Shih, A. Y., Schairer, A., Court, A. C., Goff, D. J., Prashad, S., Geron, I., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0453-9 · Cited by 106
Wellbrock, J., Latuske, E., Köhler, J., Wagner, K., Stamm, H., Vettorazzi, E., Vohwinkel, G., Klokow, M., Uibeleisen, R., Ehm, P. A. H., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1059 · Cited by 105
Self-citationSekeres, M. A., Lancet, J. E., Wood, B. L., Grove, L. E., Sandalic, L., Sievers, E. L., & Jurcic, J. G. (2012) · Haematologica · doi:10.3324/haematol.2012.066613 · Cited by 96
Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., Dickinson, M. J., Drummond, M., Assouline, S., Hashemyan, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139717 · Cited by 91
Aberrant Activation of the Hedgehog Signaling Pathway in Malignant Hematological Neoplasms
Ok, C. Y., Singh, R. R., & Vega, F. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.009 · Cited by 86
Tibes, R., Al‐Kali, A., Oliver, G. R., Delman, D. H., Hansen, N., Bhagavatula, K., Jayaram, M., Rakhshan, F., Wood, T., Foran, J. M., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0211-8 · Cited by 57
Burnett, A. K., Russell, N. H., Culligan, D. J., Cavanagh, J. D., Kell, J., Wheatley, K., Virchis, A., Hills, R. K., & Milligan, D. W. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09165.x · Cited by 56
Wei, A. H., Strickland, S. A., Roboz, G. J., Hou, J., Fiedler, W., Lin, T. L., Martinelli, G., Walter, R. B., Enjeti, A. K., Fakouhi, K., et al. (2016) · Blood · doi:10.1182/blood.v128.22.102.102 · Cited by 45
Self-citationBurnett, A. K., Hills, R. K., Hunter, A., Milligan, D. W., Kell, J., Wheatley, K., Yin, J. A. L., Mcmullin, M., Cahalin, P. A., Craig, J. I. O., et al. (2011) · Leukemia · doi:10.1038/leu.2011.59 · Cited by 40
Burnett, A. K., Russell, N. H., Hills, R. K., Panoskaltsis, N., Khwaja, A., Hemmaway, C. J., Cahalin, P. A., Clark, R. E., & Milligan, D. W. (2015) · Leukemia · doi:10.1038/leu.2015.38 · Cited by 37
Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting Challenges
Green, S. D., & Koenig, H. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00480 · Cited by 35
Heidel, F. H., Arreba-Tutusaus, P., Armstrong, S. A., & Fischer, T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1436 · Cited by 30
Self-citationLow-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia
Vey, N. (2020) · Therapeutic Advances in Hematology · doi:10.1177/2040620720913010 · Cited by 26
Heiblig, M., Elhamri, M., Tigaud, I., Pleșa, A., Barraco, F., Labussière, H., Ducastelle, S., Michallet, M., Nicolini, F. E., Plesa, C., et al. (2015) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2016.009 · Cited by 25
Kish, T. D., & Corry, L. (2016) · PubMed · Cited by 23
Individualizing Treatment for Newly Diagnosed Acute Myeloid Leukemia
Reville, P. K., & Kadia, T. M. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-0710-x · Cited by 6
Progress in acute myeloid leukaemia: small molecular inhibitors with small benefits
Hilal, T. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1015 · Cited by 4
Naoe, T. (2020) · PubMed Central · doi:10.18999/nagjms.82.2.151 · Cited by 4
Cited by
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges
Shallis, R. M., Wang, R., Davidoff, A., Ma, X., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.04.005 · Cited by 941
Acute myeloid leukemia: current progress and future directions
Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00425-3 · Cited by 776
Metadata
- Authors
- Cortes, J. E., Heidel, F. H., Hellmann, A., Fiedler, W., Smith, B. D., Robak, T., Montesinos, P., Pollyea, D. A., DesJardins, P., Ottmann, O., Ma, W. W., Shaik, M. N., Laird, A. D., Zeremski, M., O’Connell, A., Chan, G., & Heuser, M.
- Venue
- Leukemia
- Published
- 2018-12-16
- Volume
- 33
- Issue
- 2
- Pages
- 379-389
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2905344869
- Cited by
- 496
- References
- 42
- FWCI
- 43.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.